Campus Plus, Science and Technology Australia, and Cruxes Innovation to Deliver Industry PHD Program
Posted: 15 December Campus Plus, Science & Technology Australia, and Cruxes Innovation are delighted to have been chosen to deliver the new National Industry PhD program for the Department of Education. The National Industry PhD Program will powerfully…
Breaking ground: Moderna’s big build begins
Posted: 14 December In an important milestone for securing access to mRNA vaccines and enhancing medical research and development in Australia, global biotech Moderna has commenced construction of its new manufacturing facility at Monash University’s Clayton campus in…
CSL opens new Australian Plasma Fractionation Facility
Posted: 14 December CSL has today unveiled the future of plasma manufacturing in Australia with the opening of their $900 million Plasma Fractionation Facility in Victoria, the largest of its kind in the Southern Hemisphere. This is part…
Could insulin come in a pill? How a molecule that mimics insulin may advance diabetes research
Posted: 14 December WEHI researchers have answered a 100-year-old question in diabetes research: can a molecule different to insulin have the same effect? The findings provide important insights for the future development of an oral insulin pill. The…
Positive AZD0466 clinical data presented by AstraZeneca
Posted: 14 December Starpharma announces preliminary AZD0466 clinical trial results from the ongoing Phase 1/2 trial in patients with advanced relapsed/refractory leukemia (NCT04865419), presented by Starpharma’s partner AstraZeneca at the 2022 American Society of Hematology (ASH) Annual Meeting. The…
Clarity 2.0 COVID-19 Study Outcome
Posted: 14 December Dimertix Limited a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, confirmed that the CLARITY 2.0 investigator-led study of DMX-200200 in COVID-19 patients has reported top line data. In total, 49 patients were recruited…
Positive Results Confirm EXO-NET Utility for EV-Based Ovarian Cancer Test Development
Posted: 14 December INOVIQ Limited is pleased to announce that the Ovarian Cancer 97 study (OC97) has been completed by the Centre for Clinical Research, The University of Queensland (UQ), confirming the utility of EXO-NET for EV biomarker…
Post-Market Clinical Study in COVID-19 Patients
Posted: 12 December Starpharma Holdings Limited announced that it has commenced recruitment in the UK for a post-market clinical study of its broad-spectrum antiviral barrier nasal spray, VIRALEZE, in patients with COVID-19, following receipt of the necessary regulatory…
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
Posted: 8 December Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announces the successful scale-up of the manufacturing of its lead product candidate eftilagimod alpha, a first-in-class soluble LAG-3 protein, with…
Polygenic risk scores for cardiovascular diseases and type 2 diabetes
Posted: 8 December Genetic Technologies Limited, a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is delighted to announce the publication of a peer-reviewed paper describing the development and validation of the polygenic risk…
Imagion presents MagSense interim study results at breast cancer meeting
Posted: 8 December Imagion Biosystems Limited, a company dedicated to improving healthcare through the earlier detection of cancer, presented interim data from the Company’s ongoing Phase I study for its MagSense HER2 breast cancer imaging agent at the 2022…
Tessara Therapeutics and NETRI to collaborate on the development of next generation 3D brain-on-a-chip model
Posted: 5 December Tessara Therapeutics Pty Ltd and NETRI have established a collaboration to develop a family of next generation organ-on-chip models for neurological disease. The new models will combine Tessara’s RealBrain® 3D neural micro-tissues with NETRI’s NeoBentoTM…
